Search

Search Constraints

You searched for: Author/Creator Reiman, Anthony

Search Results

1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

2. Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. Issue 4 (31st August 2022)

3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Issue 8 (August 2016)

4. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Issue 10292 (19th June 2021)

5. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. (5th April 2022)

6. Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. (26th September 2022)

7. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada. (27th June 2021)

8. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. (July 2019)

9. The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership. (6th November 2021)

10. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma. (16th February 2021)